Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.
about
MSH6 syndromeDNA mismatch repair: molecular mechanism, cancer, and ageingCadmium inhibits mismatch repair by blocking the ATPase activity of the MSH2-MSH6 complexThe alternating ATPase domains of MutS control DNA mismatch repairHereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Lynch syndrome among gynecologic oncology patients meeting Bethesda guidelines for screening.A knowledge-based framework for the discovery of cancer-predisposing variants using large-scale sequencing breast cancer dataSuspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicityRole of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndromeLoss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history.Hereditary colon cancer: lynch syndromeGenotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families.Genetic predisposition to colorectal cancer: where we stand and future perspectivesTumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.Msh6 protects mature B cells from lymphoma by preserving genomic stability.Colon cancer associated genes exhibit signatures of positive selection at functionally significant positionsTumours with loss of MSH6 expression are MSI-H when screened with a pentaplex of five mononucleotide repeats.A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory.Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.Anticipation in lynch syndrome: where we are where we goIdentification of cancer patients with Lynch syndrome: clinically significant discordances and problems in tissue-based mismatch repair testing.Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors.Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer.Low prevalence of germline hMSH6 mutations in colorectal cancer families from SpainMutually exclusive promoter hypermethylation patterns of hMLH1 and O6-methylguanine DNA methyltransferase in colorectal cancer.Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6Biochemical analysis of the human mismatch repair proteins hMutSα MSH2(G674A)-MSH6 and MSH2-MSH6(T1219D)Improved multiplex ligation-dependent probe amplification analysis identifies a deleterious PMS2 allele generated by recombination with crossover between PMS2 and PMS2CL.Molecular testing for microsatellite instability and its value in tumor characterization.Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps.Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.Recently identified colon cancer predispositions: MYH and MSH6 mutations.Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency.MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease.Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability.Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach.Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohortsMSH6 missense mutations are often associated with no or low cancer susceptibilityImmunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing
P2860
Q22001356-DCD05CC7-1000-421B-A04B-E2255A502BD3Q24647002-07AEB447-1293-43EF-8F78-EE953569F958Q24798955-0C6574FC-08B4-43C4-BF47-CA5BBA870E9EQ27640375-4794D274-61D3-437B-B642-1ED357ED605BQ28085485-88CF3DCA-67C5-4BC2-8D7A-C37D93CA9435Q33653935-381481AF-483B-4604-A547-566E420D5474Q33750026-BD69D202-39BA-4C54-9109-555CE128882FQ33769290-4B941677-B94C-4A18-9998-3CCAE1B22FB8Q33817058-8CBE8B68-2E7F-400D-8B11-63E90C284EFBQ33865925-E1695B04-5BBE-4F51-84A5-D22972EB4142Q33910331-61FC3E6D-68C9-4035-882B-2ADB6E5587A0Q33918280-DD0C0D35-903E-462E-84E2-B9F72D8269B2Q33939068-A2853AC0-3E70-470F-8F71-C3DB1F5130B8Q34008801-F2FE7F3F-3038-493C-8213-B0B8CD8FE7D3Q34252077-FFFF0012-C4FE-48C8-AED1-E165539F567FQ34254602-E06DC3EE-1EDA-46B4-8F1C-78FECA6BED78Q34334316-724361E2-E8BC-4257-9204-1D2E2FAC2C74Q34433799-49AA67CE-104F-4AE1-8C53-B03E50373166Q35013990-A2E729A8-5838-4C49-BC06-A9D7D6D1F9E2Q35022384-9DCF8D31-852D-44C5-BB40-3D188D85878FQ35560811-8700FC9E-09F5-4F05-A467-1CDCCDD09784Q35740291-9BF8032E-14BB-4E97-8064-91FB2FE0FFCFQ35748966-B409CB98-5F09-4210-BBC7-C30F63091E78Q35760971-03051161-ABF4-495C-8550-543A6215A63CQ35777640-EDCB9A39-898A-4CEE-9851-56BA5FBDD0BFQ35790060-ADB04B3E-D804-4DB2-92C9-E06BF9287060Q35836701-7D76C5F5-CEE7-46E4-AC4B-B2A9E37BE5BBQ35880032-3D63C176-C634-4709-9295-5B82DF8ECFCFQ36098562-C3B7A027-0420-484B-8CA7-F9B973ED6FA5Q36192733-AA521C6E-A4EF-4F50-A469-3161E18FC330Q36289277-A4D58CD2-E927-4518-A2D4-37CE25FE0B38Q36385676-54C72530-EDBA-42C8-BDF7-6F92A6CEE726Q36484887-DF7816C2-0F2E-4D12-891F-C57BCC3AC439Q36492931-407D0F02-8BE8-4445-8DBB-FFFD23228C87Q36611645-E050B8D5-6327-4174-9F94-99C38A4EE7FFQ36612580-FC4D79AD-4E10-480D-B8B4-6B4AB3ADC1C5Q36646164-61F79240-38D2-444C-AD33-ABCBBE9E00E4Q36677899-BD99F335-7C4D-43B0-821B-2FF70CD01A43Q36695748-D4BF093D-C653-48B6-B55C-069EE8098516Q36734614-D762923F-4EC8-429C-ACBE-53B3460B8585
P2860
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2002
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular and clinical charact ...... arriers of a germline variant.
@en
Molecular and clinical charact ...... arriers of a germline variant.
@nl
type
label
Molecular and clinical charact ...... arriers of a germline variant.
@en
Molecular and clinical charact ...... arriers of a germline variant.
@nl
prefLabel
Molecular and clinical charact ...... arriers of a germline variant.
@en
Molecular and clinical charact ...... arriers of a germline variant.
@nl
P2093
P2860
P356
P1476
Molecular and clinical charact ...... arriers of a germline variant.
@en
P2093
Arend Karrenbeld
Ate G J van der Zee
Charles H C M Buys
Elisabeth G E de Vries
Harry Hollema
Jan H Kleibeuker
Jannet M Hordijk-Hos
Maran J W Berends
Rob G J Mensink
Robert M W Hofstra
P2860
P356
10.1086/337944
P407
P577
2002-01-01T00:00:00Z